A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Public ClinicalTrials.gov record NCT02596971. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma
Study identification
- NCT ID
- NCT02596971
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 91 participants
Conditions and interventions
Interventions
- Atezolizumab Drug
- Bendamustine Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Obinutuzumab Drug
- Prednisone Drug
- Rituximab Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2015
- Primary completion
- Apr 10, 2018
- Completion
- May 7, 2020
- Last update posted
- May 23, 2021
2015 – 2020
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Rocky Mountain Cancer Center - Aurora | Aurora | Colorado | 80012 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| University Miami | Miami | Florida | 33136 | — |
| New York Uni Medical Center | New York | New York | 10016 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute | Springfield | Oregon | 97477 | — |
| Western Pennsylvania Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| Texas Oncology-Tyler | Irving | Texas | 75063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02596971, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2021 · Synced Apr 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02596971 live on ClinicalTrials.gov.